Why apply?
Discover how this programme helps medicines-manufacturing SMEs access expertise, infrastructure and funding to grow.
SMEs within the Medicines Manufacturing sector are key drivers of innovation but face systemic challenges:
- Limited access to capital and lab infrastructure.
- High costs for early-stage development and validation.
- Fragmented support and regulatory navigation barriers.
Together, the Catapults cover the full spectrum of medicines manufacturing, from discovery and preclinical validation (MDC), through scalable process and formulation development (CPI), to the industrialisation of advanced therapies such as cell and gene therapies (CGTC).
CatapultRx aims to addresses the above issues by:
- Providing SMEs with access to Catapult expertise and facilities.
- Accelerating scale-up, commercial readiness or investment potential of the innovation.
Through this, we aim to:
- Support the growth of businesses within the Medicines Manufacturing Sector.
- Strengthening UK competitiveness in medicines manufacturing.
- Supporting the creation of high-value jobs and economic growth.